Protalix BioTherapeutics Q3 2026 earnings
Revenue and operating income grew sequentially and year-over-year, supported by Elfabrio sales and improved margins.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $21.9M | +23% | +10% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.05 | +67% | +0.0 | Ex. 99.1, income statement |
| Net income | $3.96M | +68% | +5% | Ex. 99.1, income statement |
| Adj. EBITDA | $6.2M | +N/A | +32% | Ex. 99.1, income statement |
| Adj. EBITDA margin | 28.3% | +N/A | +5.0 pp | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Selling goods | $21.8M | +23% | 99% | Elfabrio sales |
| License and R&D services | $91K | -49% | 0% | Lower services provided to Chiesi |
Margins and costs
- Gross margin N/A
- Operating expenses $17.2M (+7% YoY)
- One-offs in the quarter not stated in the 8-K
- Effective tax rate 14% (prior-year 12%, year-to-date 15%)
- Non-GAAP bridge Financial income net of expenses added back to GAAP operating income to arrive at Adj. EBITDA.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash and deposits | $48.5M | $40.7M | $25.8M | +19% |
| Total revenue (YTD) | $75.6M | $53.6M | $25.8M | +194% |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| 2026 Revenue | $75M - $85M | $75M - $85M | No change |
What drove it
- Revenue story Selling goods grew 23% YoY to $21.8M, driven by continued Elfabrio penetration; license and R&D services declined 49% YoY to $91K due to lower services provided to Chiesi.
- EPS story EPS growth driven by higher revenue and improved operating margins.
- One-off check None disclosed.
The good
- Operating income of $4.0M (+89% YoY)
- Adj. EBITDA margin expanded 5.0 pp to 28.3%
The bad
- License and R&D services declined 49% YoY
The ugly
- none
Open questions
- What specific factors caused the decline in license and R&D services?
- What is the timeline for the Phase 2 RELEASE study top-line results?
Full release
Protalix BioTherapeutics (PLX) earnings release, November 10, 2026
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. ET
CARMIEL, Israel, November 10, 2026
-- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the third quarter ended September 30, 2026, and provided a business and clinical update.
“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities,” said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics. “We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity. Current uricase therapy has challenges including infusion burden, immunogenicity with loss of efficacy, and safety concerns. We designed PRX-115 for reduced immunogenicity and less frequent dosing that could reduce infusion burden and improve patient adherence. We look forward to top-line results from the RELEASE study in the second half of 2027.”
Third Quarter 2026 Operational Update
Elfabrio® for Fabry Disease
PRX-115 for uncontrolled gout
Phase 2 RELEASE Study
ACR 2026 Phase 1 Data
Focus on Rare Renal Indications (Preclinical Programs)
Financial Outlook: Building Durable Growth and Long–Term Value
The Company has no outstanding debt or warrants.
Priorities remain consistent:
The Company reaffirms its 2026 revenue guidance and expects to meet or exceed these ranges:
Financial statements
Income Statement
Nine Months Ended — (Unaudited)
| Nine Months Ended – September 30, 2026 | Nine Months Ended – September 30, 2025 | Three Months Ended – September 30, 2026 | Three Months Ended – September 30, 2025 | |
|---|---|---|---|---|
| REVENUES FROM SELLING GOODS | 49,081 | 43,108 | 21,834 | 17,673 |
| REVENUES FROM LICENSE AND R&D SERVICES | 26,490 | 514 | 91 | 178 |
| TOTAL REVENUE | 75,571 | 43,622 | 21,925 | 17,851 |
| COST OF REVENUES | -19,765 | -22,374 | -7,876 | -8,324 |
| RESEARCH AND DEVELOPMENT EXPENSES, NET | -16,700 | -13,934 | -6,923 | -4,467 |
| SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES | -9,241 | -8,156 | -3,079 | -2,929 |
| OPERATING INCOME (LOSS) | 29,865 | -842 | 4,047 | 2,131 |
| FINANCIAL EXPENSES | -441 | -808 | -24 | -180 |
| FINANCIAL INCOME | 1,199 | 818 | 599 | 288 |
| FINANCIAL INCOME, NET | 758 | 10 | 575 | 108 |
| INCOME (LOSS) BEFORE TAXES ON INCOME | 30,623 | -832 | 4,622 | 2,239 |
| TAXES ON INCOME (TAX BENEFIT) | 4,568 | 268 | 661 | -116 |
| NET INCOME (LOSS) | 26,055 | -1,100 | 3,961 | 2,355 |
| EARNINGS (LOSS) PER SHARE OF COMMON STOCK: | ||||
| BASIC | 0.33 | -0.01 | 0.05 | 0.03 |
| DILUTED | 0.31 | -0.01 | 0.05 | 0.03 |
| USED IN COMPUTING EARNINGS (LOSS) PER SHARE: | ||||
| BASIC | 80,077,803 | 78,225,112 | 80,455,731 | 79,281,685 |
| DILUTED | 83,000,983 | 78,225,112 | 83,586,774 | 80,814,564 |
Balance Sheet
September 30, 2026 — (Unaudited)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | 22,035 | 14,680 |
| Short-term bank deposits | 26,503 | 15,593 |
| Restricted deposit | 729 | 702 |
| Accounts receivable | 13,913 | 8,840 |
| Other assets | 1,395 | 1,129 |
| Inventories | 34,297 | 25,729 |
| Total current assets | 98,872 | 66,673 |
| NON-CURRENT ASSETS: | ||
| Funds in respect of employee rights upon retirement | $- | 578 |
| Property and equipment, net | 5,769 | 4,879 |
| R&D grant receivable | 3,030 | |
| Deferred income tax asset | 2,304 | 2,516 |
| Operating lease right of use assets | 8,267 | 7,700 |
| Total assets | 118,242 | 82,346 |
| Accounts payable and accruals: | ||
| Trade | 4,779 | 5,259 |
| Other | 23,769 | 19,875 |
| Operating lease liabilities | 1,685 | 1,384 |
| Total current liabilities | 30,233 | 26,518 |
| LONG TERM LIABILITIES: | ||
| Liability for employee rights upon retirement | $- | 661 |
| Operating lease liabilities | 7,460 | 6,937 |
| Total long-term liabilities | 7,460 | 7,598 |
| Total liabilities | 37,693 | 34,116 |
| COMMITMENTS | ||
| STOCKHOLDERS’ EQUITY | 80,549 | 48,230 |
| Total liabilities and stockholders’ equity | 118,242 | 82,346 |
Cash Flow
From the 10-Q · Nine Months Ended — (Unaudited)
| Nine Months Ended – September 30, 2026 | Nine Months Ended – September 30, 2025 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | 26,055 | -1,100 |
| Adjustments required to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Share-based compensation | 1,531 | 1,565 |
| Depreciation | 1,231 | 1,078 |
| Financial expenses, net | 192 | 136 |
| Changes in accrued liability for employee rights upon retirement | -59 | 14 |
| Changes in deferred income tax asset | 212 | 177 |
| Gain on amounts funded in respect of employee rights upon retirement | -18 | |
| Changes in operating assets and liabilities: | ||
| Increase in accounts receivable-trade and other assets | -5,369 | -11,768 |
| Changes in operating lease right of use assets, net | 138 | -62 |
| Increase in inventories | -8,568 | -12 |
| Increase in R&D grant receivable | -2,972 | |
| Increase (decrease) in accounts payable and accruals | 3,138 | -4,033 |
| Net cash provided by (used in) operating activities | 15,529 | -14,023 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Investment in bank deposits | -24,065 | $- |
| Short-term deposit withdrawal | 13,000 | |
| Purchase of property and equipment | -2,091 | -1,235 |
| Amounts funded in respect of employee rights upon retirement, net | -40 | -19 |
| Increase in restricted deposit | -27 | |
| Net cash used in investing activities | -13,223 | -1,254 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock under the Sales Agreement, net | 4,210 | 6,812 |
| Exercise of warrants and options | 523 | 2,368 |
| Net cash provided by financing activities | 4,733 | 9,180 |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | 316 | -16 |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 7,355 | -6,113 |
| BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 14,680 | 19,760 |
This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. These estimates are based on management’s current
estimates, which are subject to change and may be updated accordingly. See “Forward-Looking Statements” for additional information.
Third Quarter and Year-to-Date 2026 Financial Highlights
Conference Call and Webcast Information
The Company will host a conference call today, November 10, at 8:00 am ET, to review the financial results and provide a business update. To participate in the conference call, please dial the following numbers prior to the start of the call:
Conference Call Details
Date:
November 10, 2026
Time:
8:00 a.m. Eastern Time (ET)
Toll Free:
1-877-423-9813
International:
1-201-689-8573
Israeli Toll Free:
1-809-406-247
Conference ID:
13763420
Call me™: https://tinyurl.com/3awxvdvm
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
The conference will be webcast live from the Protalix website and will be available via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://tinyurl.com/ye6k6b3n
Conference ID:
13763420
Participants are requested to access the websites at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Protalix website, at the above link.
About Uncontrolled Gout
Gout is a metabolic disorder characterized by elevated blood uric acid that causes recurrent inflammatory arthritis and joint damage. An estimated 11.3 million people in the U.S. have gout.¹
Rheumatologists report that approximately 25% of their patients have blood uric acid levels above target, which can lead to uncontrolled gout.²
An estimated 180,000 patients in the U.S. have uncontrolled gout.²
Uncontrolled gout is a severe disease with high morbidity, severe pain, and low quality of life.
About PRX-115
PRX-115 is a recombinant PEGylated uricase in development for uncontrolled gout, produced using Protalix’s ProCellEx® plant cell-based protein expression platform. Current uricase therapy has challenges including infusion burden, immunogenicity with loss of efficacy, and safety concerns. PRX-115 is designed for high specific activity, prolonged circulating half-life, and reduced immunogenicity.³
In the Phase 1 study of adults with elevated plasma uric acid levels, single infusions of PRX-115 lowered plasma uric acid levels rapidly and were generally well tolerated. At 36 mg, mean plasma uric acid stayed below the 6.0 mg/dL target for up to 12 weeks after a single infusion. Protalix believes PRX-115 has best-in-class potential for uncontrolled gout.
About the Phase 2 RELEASE Study (PRX-115)
RELEASE (NCT07280156) is a Phase 2, double-blind, placebo-controlled study of PRX-115 in patients with uncontrolled gout. The study tests a fixed 36 mg dose in five treatment arms of 30 patients each: PRX-115 every 4 weeks without methotrexate, PRX-115 every 4, 6, or 8 weeks with methotrexate, and placebo. The primary endpoint is the proportion of patients who demonstrated a reduction in serum uric acid levels to below 6.0 mg/dL for at least 80% of the time during Month 6. Top-line results are expected in the second half of 2027.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix’s proprietary plant cell-based expression system, ProCellEx®... (truncated)t cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.¹
GlobalData, August 2025²
Protalix internal research and proprietary market research (75 rheumatologists).³
Schwabe C, Cohen-Barak O, Cole A, et al. Prolonged plasma urate-lowering after a single intravenous administration of PRX-115, a novel PEGylated uricase, in participants with elevated urate levels. Presented at: ACR Convergence 2024. Abstract L05.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix’s development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.
Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements generally relate to future events or the Company’s future financial or operating performance, including the 2026 financial outlook described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. The terms “anticipate,” “believe,” “estimate,” “expect,” “can,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings of the clinical trial. Factors that might cause material differences include, among others: risks related to the commercialization of Elfabrio®
(pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease; risks relating to Elfabrio’s market acceptance, competition, reimbursement, and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product; risks associated with global conditions and developments such as new or increased tariffs, treaties, trade policies, taxes, and other limitations on cross-border operations, which may adversely impact our business, results of operations, and financial condition; risks related to the regulatory approval and commercial success of our other product and product candidates, if approved; risks related to our expectations with respect to the projected market of our products and product candidates; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and/or inability to monitor patients adequately during or after treatment; the risk that the results of our clinical trials of our product candidates will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; the possible disruption of our operations due to the regional conflict in Iran and the military actions between Israel and Iran, the Hamas terrorist organization located in the Gaza Strip, Hezbollah, the Houthis terrorist group that controls parts of Yemen, and others, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors, and customers, and
... (truncated) working capital; risks relating to our evaluation and pursuit of strategic partnerships; risks relating to our ability to manage our relationship with our collaborators, distributors, and partners, including, but not limited to, Pfizer Inc. and Chiesi Farmaceutici S.p.A.; risks related to the amount and sufficiency of our cash and cash equivalents and short-term bank deposits; risks relating to changes to interim, top-line or preliminary data from clinical trials that we announce or publish; risks relating to the compliance by Fundação Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health with its purchase obligations under our supply and technology transfer agreement that we entered into with Fiocruz in June 2013, which may have a material adverse effect on us and may result in our terminating such agreement; risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector; our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies; risks related to our supply of drug products to Pfizer; potential product liability risks, and risks of securing adequate levels of related insurance coverage; the possibility of infringing a third-party’s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; risks relating to changes in healthcare laws, rules, and regulations in the United States or elsewhere; and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law. You are cautioned not to place undue reliance on these forward-looking statements.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306 mmoyer@lifesciadvisors.com